P Morandi

Summary

Country: Italy

Publications

  1. ncbi request reprint Biological agents and gemcitabine in the treatment of breast cancer
    P Morandi
    Michelangelo Foundation, Medical Oncology Department, S Bortolo Hospital, Vicenza, Italy
    Ann Oncol 17:v177-80. 2006
  2. ncbi request reprint Cardiac toxicity of high-dose chemotherapy
    P Morandi
    Divisione Oncologia Medica, Ospedale San Bortolo, Vicenza, Italy
    Bone Marrow Transplant 35:323-34. 2005
  3. ncbi request reprint Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide
    P Morandi
    Division of Medical Oncology, San Bortolo Hospital, Vicenza, Italy
    Bone Marrow Transplant 28:277-82. 2001
  4. doi request reprint Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:1404-10. 2008
  5. doi request reprint p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer
    A Ravaioli
    Department of Oncology, Ospedale Infermi, Rimini and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola FC Italy
    Ann Oncol 19:660-8. 2008
  6. ncbi request reprint Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer
    N Cabioglu
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Ann Oncol 18:1021-9. 2007
  7. ncbi request reprint High-dose medroxyprogesterone in disseminated breast cancer. Correlation between bioavailability and clinical response
    A Fornasiero
    Department of Medical Oncology, U.L.S.S. 21, Padova, Italy
    Tumori 73:617-21. 1987
  8. ncbi request reprint Obesity may decrease the amenorrhea associated with chemotherapy in premenopausal breast cancer patients
    K Altundag
    Ann Oncol 16:333; author reply 333-4. 2005
  9. ncbi request reprint Cyclooxygenase-2 inhibitor and cisplatin combination as a radiosensitizer in the treatment of head and neck cancer patients
    O Altundag
    Ann Oncol 15:1444-5. 2004
  10. pmc Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations
    M Cristofanilli
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 19:1713-9. 2008

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Biological agents and gemcitabine in the treatment of breast cancer
    P Morandi
    Michelangelo Foundation, Medical Oncology Department, S Bortolo Hospital, Vicenza, Italy
    Ann Oncol 17:v177-80. 2006
  2. ncbi request reprint Cardiac toxicity of high-dose chemotherapy
    P Morandi
    Divisione Oncologia Medica, Ospedale San Bortolo, Vicenza, Italy
    Bone Marrow Transplant 35:323-34. 2005
    ..New 2D echo-based techniques and circulating markers of cardiac function hold promise for allowing identification of patients at high risk for and early diagnosis of cardiac toxicity...
  3. ncbi request reprint Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide
    P Morandi
    Division of Medical Oncology, San Bortolo Hospital, Vicenza, Italy
    Bone Marrow Transplant 28:277-82. 2001
    ..ECG (ie QRS voltages ) and Echo (ie E/A ratio) monitoring leads us to hypothesize that slight interstitial edema with reduction of LV diastolic compliance may be initial signs of cardiac dysfunction in this clinical setting...
  4. doi request reprint Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:1404-10. 2008
    ....
  5. doi request reprint p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer
    A Ravaioli
    Department of Oncology, Ospedale Infermi, Rimini and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola FC Italy
    Ann Oncol 19:660-8. 2008
    ..We investigated these proteins in two International Breast Cancer Study Group trials studying node-negative early breast cancer...
  6. ncbi request reprint Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer
    N Cabioglu
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Ann Oncol 18:1021-9. 2007
    ..Expression of CXCR4 and CCR7 along with the biomarkers HER2-neu and epidermal growth factor receptor (EGFR) was investigated in inflammatory breast cancer (IBC) to evaluate their prognostic implications...
  7. ncbi request reprint High-dose medroxyprogesterone in disseminated breast cancer. Correlation between bioavailability and clinical response
    A Fornasiero
    Department of Medical Oncology, U.L.S.S. 21, Padova, Italy
    Tumori 73:617-21. 1987
    ..group. Response rate and MPA plasma concentrations were correlated, and a drug level of 80 ng/ml, by means of a GLC method, seems to identify a subset of patients with high probability of response. Only mild toxic effects were recorded...
  8. ncbi request reprint Obesity may decrease the amenorrhea associated with chemotherapy in premenopausal breast cancer patients
    K Altundag
    Ann Oncol 16:333; author reply 333-4. 2005
  9. ncbi request reprint Cyclooxygenase-2 inhibitor and cisplatin combination as a radiosensitizer in the treatment of head and neck cancer patients
    O Altundag
    Ann Oncol 15:1444-5. 2004
  10. pmc Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations
    M Cristofanilli
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 19:1713-9. 2008
    ..We tested the activity of imatinib mesylate in MBC with overexpression of PDGFR or c-kit. Additionally, we sought to determine the biological correlates and immunomodulatory effects...